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Background 
Insecticide-impregnated collars for dogs, the reservoir of Leishmania infantum, have been 
repeatedly shown to affect sandfly feeding success and mortality, and to reduce canine 
infection incidence (Reithinger et al., 2001, Maroli et al., 2001, David et al., 2001, Killick-
Kendrick, 1997, Halbig et al., 2000), in addition to childhood seroconversion incidence when 
distributed at the community level (Gavgani et al., 2002a). No studies have tested this 
intervention approach to reduce the incidence of human VL disease. 
 
Objectives 
The objectives of the study are (1) to measure the efficacy of the collar intervention against 
VL case incidence in children <11yrs old (the high-risk group); (2) to evaluate the operational 
logistics of collar implementation and sustainability by the local Leishmaniasis Control 
Program; and (3) to assess potential causes for any between village variation in impact on VL 
incidence, including (i) community coverage with collars; (ii) dog-owner compliance; and 
(iii) implementation logistics. 
 
Methods 
Study location   
The study will enroll villages in the rural region of the Kalaybar and Ahar administration 
districts in East Azerbaijan province, NW Iran (38688131N; 4321696E). In the study region, 
sandflies are active from late June to the beginning of October indicating an annual transmission 
season of about 4 months. Two species of sandfly Phlebotomus (Larroussius) perfeliewi 
transcaucasicus and Ph. (L.) kandelakii are the likely vectors of L. infantum in NW Iran where 
peridomestic transmission is clearly demonstrated (Gavgani et al., 2002b, Gavgani et al., 
2002a). 
 
The study is designed to be conducted in collaboration with the District Ministry of Public 
Health (DTARH) in Kalaybar and Ahar, which is responsible for the regional VL Control 
Program. DTARH oversees the District Health Centres (DHCs) that coordinate activities of 
12 provincial Rural Health Centres (RHCs), each run by fully trained medical staff and health 
officers. Each RHC supervises about 10 village health posts where resident Health Promoters 
are responsible for disease surveillance, control implementation, data collection, and facilitate 
suspect VL cases attendance at the RHCs. The RHCs provide free VL diagnostic testing and 
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treatment services, and refer those needing more specialist hospitalization to the DHCs or 
district hospital.  
 
Study design 
The trial is designed by the PI and co-Is (“the scientists”) but implemented by DTARH in 
order to measure the efficacy under operational conditions. 
 
Randomisation and treatment allocation  
The trial is designed as a pair matched-cluster randomised trial where study villages are 
designated as clusters. 
 
Village recruitment 
Villages will be recruited in a two-step process:  
Step 1. All 417 endemic villages in the two districts were listed with the recorded number of 
VL cases in the 4.5 years prior to the intervention (January 1998- June 2002) (based on 
DTARH records). The inclusion criteria for village recruitment were (i) that the village is 
residential and not nomadic or partially nomadic; (ii) that the human population size is >100; 
(iii) that at least 1 confirmed clinical VL case was reported between January 1998 and June 
2002, indicative of recent transmission; and (iv) that the village was not subject to recent VL 
interventions (insecticide control against vectors; culling household dogs) during the pre-
intervention period. A total 91 villages have been indicated to meet these criteria for potential 
recruitment. All villages are located >>1km apart this ensuring no treatment contamination 
between clusters by sandflies that can potentially fly distances up to c. 1km (usually only 
300m).  
 
Step 2. Village leaders will be consulted by the RHC supervisors along with the village 
Health Promotors, to seek informed agreement to be part of the trial. Dog-owners will be 
informed of the procedures, benefits and risks, regarding collaring their dogs and requested to 
provide written consent.  
 
Randomisation 
Recruited villages will be listed and ranked in descending order of childhood incidence in the 
pre-intervention period, and the top two villages paired, and then randomly assigned to either 
collar treatment or no treatment (control) by tossing a coin in the presence of observers. All 
subsequent pairs in descending order will be randomised in the same way but alternating the 
first of each subsequent pair to treatment or control group.  
 
Balance of the two arms will be inspected based on data collected by DTARH including: 
village population size, number of children <11yrs, sex, literacy and employment status, 
house numbers, dog population sizes, dog occupation (shepherd vs guard or pet). During the 
trial period, surveys will be conducted by village Health Promotors to inspect these 
demographics. They will also monitor any other activities associated with VL control 
(reservoir or vector control, distribution of bednets, etc).  
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Intervention 
Deltamethrin-impregnated collars (Scalibor®ProtectorBand) will be provided by Intervet 
International free of charge, and fitted following manufacturer’s recommendations. With dog-
owner consent, collars will be fitted to all eligible dogs before the start of each transmission 
season over 4 consecutive years (2002-2005) giving 48 months follow-up. The collars have an 
effective duration of ³6 months. The exclusion criteria for collaring a dog will follow product 
label indications (i) dogs <3m old based on owner information; and (ii) dogs showing signs of 
pregnancy or lactation.  
 
Implementation  
The intervention will be implemented by the Heads of the DTARH operational DHCs in 
Kalaybar and Ahar, and their respective village-based Health Promoters. Information on 
collar fitting and replacement logistics, and dog-owner compliance, will be collected by 
village Health Promotors following full training in the initial year by the scientific team. The 
team will monitor the dates and numbers of collars provided to DTARH also ensuring that 
they receive sufficient collars for replacement. 
 
Case definition and reporting 
VL case detection, diagnosis and reporting will follow standard local MoH procedures. 
Suspect cases are attended at RHCs where free VL diagnostic testing and treatment services 
are provided; cases needing hospitalization are sent to the DHCs or district hospital. Cases are 
confirmed by trained physicians, on presentation of clinical signs including prolonged fever, 
lymphadenopathy, and hepatosplenomegaly, and in the presence of a positive Direct 
Agglutination Test (DAT) and/or detection of Leishmania by microscopic examination of 
bone marrow aspirate. DATs were performed in the VL laboratory in the DHCs following 
established MoH protocols, designating DAT titres ³1/3200 as indicative of L. infantum 
infection. Patients with raised but negative DAT titres in the presence of mild clinical signs 
are usually considered at risk and thus re-examined at 2-3m intervals to detect ascending titres 
and clinical progression. All confirmed cases, receive treatment with registered antimonial 
drugs (Meglumine antimoniate (Glucantime, Sanofi) or sodium stibogluconate (Pentostam, 
GSK) following WHO guidelines. Amphotericin B is currently used in Iran to treat cases 
resistant to pentavalent antimonials. 
 
Data management and masking 
Following the routine DTARH case reporting processes, confirmed VL case details will be 
supplied by the RHCs, DHCs and district hospital to DTARH for collation along with data on 
case age, sex, village of residence, and date when they present at the medical centre. This date 
will be used to indicate the year of transmission. DTARH will compiled anonymised data 
relevant to the study villages to provide to the PIs for data analysis. 
Village Health Promotors will not be blinded to the intervention as placebo collars are not 
available. However, the clinicians, lab technicians and DTARH data managers will be fully 
blinded to the existence of the trial. 
 
	 4	
Trial outcomes 
The primary trial outcome measure will be the cumulative number of confirmed VL incident 
cases per study village at the end of the 48 months follow-up period. There are no current 
plans for secondary measures of the intervention efficacy. VL in Iran and elsewhere is almost 
always in children <11-year-old or younger, being the well documented high-risk group 
(Mohebali, 2001). 
 
Sample size calculations 
The sample size is calculated for a pair-matched randomised control trial (Donner, 2000), and 
based on the 249 VL cases reported amongst 13,570 children <11 years old recorded in the 91 
villages during the 4.5 years pre-intervention period (DTARH unpublished data). The average 
annual childhood incidence calculated from these records is 0.0041 (4.1 cases per thousand). 
To detect a 50% reduction in childhood incidence after 48 months follow-up, requires 39 
clusters per arm to achieve a power of 90% with α=0.05 to reject the null hypothesis. This 
assumes that there are an average 120 children per cluster, and a cluster coefficient of 
variation of κ = 0.124 following the value estimated from the previous trial of these collars in 
this region. After the final village (cluster) recruitment, sample size estimation will be 
repeated using updated values. 
   
Statistical analyses 
The intervention effect (incidence risk ratios IRR) on the cumulative childhood incidence 
over 48 months will be estimated using random-effects regression including variables 
describing the trial design (the cluster pair-matching structure, baseline village childhood 
incidence, and the attributed year of transmission), offset (scaled) to the village childhood 
population size. Interaction terms will be included to explore associations between the 
intervention effects in each year.  
Additional demographic variables will be included as a further potential adjustment to the 
effect estimates. Changes in nested model deviances will be tested by log-likelihood ratio test. 
The effect estimates will also by tested by a paired t-test of the residuals of the observed 
/expected VL case ratios per paired clusters (Donner, 2000).  
 
Ethical considerations 
The trial protocol has been approved by the Medical Ethics, Tabriz University of Medical 
Sciences, NW Iran, and the London School of Hygiene and Tropical Medicine. Communities 
will be informed about the purposes of the trial by the head of the DHCs, and informed 
consent will be obtained from village leaders and by dog owners for fitting collars. Animal 
handling procedures has been approved also by the Iranian Department of Environment, East 
Azerbaijan province division (document #5676). Retrospectively, the University of 
Warwick’s Biomedical and Scientific Research Ethics Committee (BSREC) also confirmed 
that the trial raised no significant ethical concerns due to its use of secondary anonymous 
data. 
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